Finerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease

Type 2 diabetes is the most common cause of chronic kidney disease (CKD) and end-stage renal disease. Cardiovascular risk and the risk of progression of kidney disease are very high among patients with diabetes mellitus, particularly among those with CKD. Clinical strategies to prevent cardiovascular disease and the development of new diabetic kidney disease or to slow the progression of CKD that is already present have been incorporated into clinical practice for the past three decades and include angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and, more recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors (gliflozins), such as dapagliflozin and empagliflozin. However, few of the . . .